Steven G Coca, DO Email Steven Coca
-
- Position
- ASSOCIATE PROFESSOR | Medicine, Nephrology
-
- Specialty
- Nephrology
-
- Language
- English
-
- Hospital Affiliation
- The Mount Sinai Hospital
Dr. Steven Coca is a former graduate from University of New England College of Osteopathic Medicine. He completed his medical residency and clinical nephrology fellowship at Yale University and Yale New Haven Hospital in CT. He also received a Master’s Degree in Epidemiology and Public Health during his training at Yale. He was on faculty in the Section of Nephrology for 5 years as an Assistant Professor. Currently, he is an Associate Professor of Medicine at Icahn School of Medicine at Mount Sinai. He has been an active investigator in three large NIH-funded consortiums: the Translational Research in Biomarker Endpoints in Acute Kidney Injury (TRIBE-AKI) consortium; the Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) consortium; and the CKD Biomarkers Consortium. Dr. Coca is also the PI of an ancillary study to the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial and a member of the newly formed Drug Development Tools for Kidney Disease (DDT-KD) Consortium, sponsored by the Critical Path Institute. His major research areas include using newer biomarkers to aide risk-stratification for outcomes in acute kidney injury and chronic kidney disease. His major clinical interests include AKI, CKD, electrolyte disorders, hypertension, and cardiorenal syndrome.
Certification
Nephrology
Clinical Focus
- Acute Renal Failure
- Acute Tubular Necrosis
- Chronic Renal Failure
- Dialysis
- Glomerulonephritis
- High Blood Pressure
- Nephrotic Syndrome
Education
DO, University of New England
MS, Yale University Graduate School of Arts and Sciences
Residency, Internal Medicine
Yale University School of Medicine
Fellowship, Nephrology
Yale University School of Medicine
Language
English
2013
AFMR 2013 Junior Physician Investigator Award
American Federation for Medical Research
2008
T. Franklin Williams Scholar
2008
K23 Career Development Award
NIH/NIDDK
2008
NIH Loan Repayment Program
NIH
2007
Henry Christian Award
American Federation for Medical Research
2005
Intern of the Year
Yale Primary Care Internal Medicine Program
Dr. Coca is actively involved in clinical and translational research that focuses on using biomarkers to improve risk-stratification for outcomes in acute and chronic kidney disease. The development of prognostic and predictive biomarkers may aide future clinical trials, by serving as an enrichment strategy for enrollment, and may also serve as outcomes for early phase trials of novel interventions. He has leveraged existing cohorts with banked blood and urine samples, including the TRIBE-AKI consortium, and the ACCORD trial participants to explore the prognostic, discriminative, and additional value of biomarkers in AKI and CKD. He plans to continue exploring these parameters in other large cohorts and then to design innovative trials employing biomarkers for facilitated enrollment and for better determination of efficacy of existing or new agents.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Coca during 2020 and/or 2021. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Company Founder:
- RenalytixAI
Consulting:
- Bayer
- CHF Solutions, Inc
- Relypsa
- RenalytixAI
- Tucker Ellis, LLC
- inRegen
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Verici
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- RenalytixAI
Royalty Payments:
- RenalytixAI
Scientific Advisory Board:
- RenalytixAI
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.